All In MedTech

Device Trial Radar · NCT07327528

Multicentric Pilot Study for the Application of an Endourethral Device for the Treatment of Stress Urinary Incontinence

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Relief srlNot on our public-company list
Sponsor type
Industry
First posted
Jan 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 21 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stress urinary incontinence is defined as the involuntary loss of urine during exertion or physical activity (i.e., sports) or during sneezing or coughing. Approximately 127 million women and 10 million men reported suffering from stress urinary incontinence in 2008, and current estimates are on the rise. The prevalence of stress urinary incontinence is higher in older age groups, with 10% of women and 5% of men over the age of 65 suffering from this condition. The initial management of urinary incontinence consists of basic diagnostic investigations to rule out any reversible conditions (i.e., bacterial urinary tract infections, UTIs), while conservative and non-invasive treatment options include lifestyle changes, (PFMT) with or without biofeedback, and bladder retraining.

Conditions

  • Urinary Incontinence , Stress

Interventions

  • UroRelief, a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence.Device

    UroRelief is a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence. The device is designed to be inserted through the urethra using a routine endoscopic procedure with a resectoscope. Once in place, the device is completely inside the body with no visible parts outside and can restore urinary continence control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety of UroReliefTime frame: 18 months
  2. The safety of UroReliefTime frame: 18 months
  3. The safety of UroReliefTime frame: 18 months

1 more outcomes with a free account

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Senese - Policlinico Santa Maria alle Scotte

    Siena, Italy · Recruiting

  • Azienda Ospedaliera Santa Maria di Terni

    Terni, Italy · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.